OpenLB
Open Library of Bioscience
Advanced Search
Breathe (Sheffield, England)
Jun, 2024;20 (2): 230190.

Lung cancer screening: where do we stand?

Georgia Hardavella, Armin Frille, Katherina Bernadette Sreter, Florence Atrafi, Uraujh Yousaf-Khan, Ferhat Beyaz, Fotis Kyriakou, Elena Bellou, Monica L Mullin, Sam M Janes
Author Information
  1. Georgia Hardavella: 4th-9th Department of Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Greece.
  2. Armin Frille: Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany. ORCID
  3. Katherina Bernadette Sreter: Department of Pulmonology, University Hospital Centre "Sestre Milosrdnice", Zagreb, Croatia.
  4. Florence Atrafi: Amphia Hospital, Department of Pulmonary Medicine, Breda, The Netherlands.
  5. Uraujh Yousaf-Khan: Amphia Hospital, Department of Pulmonary Medicine, Breda, The Netherlands.
  6. Ferhat Beyaz: Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands.
  7. Fotis Kyriakou: 4th-9th Department of Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Greece.
  8. Elena Bellou: 4th-9th Department of Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Greece.
  9. Monica L Mullin: Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
  10. Sam M Janes: Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK. ORCID
PMID: 39193459 DOI: 10.1183/20734735.0190-2023

Abstract

Lung cancer screening (LCS) programmes have emerged over recent years around the world. LCS programmes present differences in delivery, inclusion criteria and resource allocation. On a national scale, only a few LCS programmes have been fully established, but more are anticipated to follow. Evidence has shown that, in combination with a low-dose chest computed tomography scan, smoking cessation should be offered as part of a LCS programme for improved patient outcomes. Promising tools in LCS include further refined risk prediction models, the use of biomarkers, artificial intelligence and radiomics. However, these tools require further study and clinical validation is required prior to routine implementation.

References

  1. Radiology. 2016 Feb;278(2):563-77 [PMID: 26579733]
  2. J Thorac Oncol. 2016 Mar;11(3):334-45 [PMID: 26896032]
  3. Am J Respir Crit Care Med. 2020 Oct 1;202(7):e95-e112 [PMID: 33000953]
  4. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):758-765 [PMID: 35064064]
  5. Transl Lung Cancer Res. 2019 May;8(Suppl 1):S95-S105 [PMID: 31211110]
  6. J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [PMID: 11459866]
  7. JAMA Intern Med. 2015 Sep;175(9):1530-7 [PMID: 26214612]
  8. Healthcare (Basel). 2023 Jul 21;11(14): [PMID: 37510525]
  9. Eur Radiol. 2012 Oct;22(10):2076-84 [PMID: 22814824]
  10. CA Cancer J Clin. 2024 Jan-Feb;74(1):50-81 [PMID: 37909877]
  11. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):698-701 [PMID: 35373266]
  12. N Engl J Med. 2011 Aug 4;365(5):395-409 [PMID: 21714641]
  13. Can Fam Physician. 2021 Nov;67(11):817-822 [PMID: 34772708]
  14. Transl Lung Cancer Res. 2019 May;8(Suppl 1):S77-S87 [PMID: 31211108]
  15. Ann Intern Med. 2014 Mar 4;160(5):330-8 [PMID: 24378917]
  16. Transl Lung Cancer Res. 2021 May;10(5):2356-2367 [PMID: 34164283]
  17. Biomark Insights. 2018 Jan 15;13:1177271917751608 [PMID: 29371783]
  18. Cancers (Basel). 2024 May 23;16(11): [PMID: 38893101]
  19. Eur Radiol. 2023 May;33(5):3092-3102 [PMID: 36480027]
  20. Transl Lung Cancer Res. 2021 Feb;10(2):1099-1109 [PMID: 33718048]
  21. Ann Oncol. 2021 Sep;32(9):1167-1177 [PMID: 34176681]
  22. Tumour Biol. 2012 Oct;33(5):1319-26 [PMID: 22492236]
  23. J Natl Cancer Inst. 2003 Mar 19;95(6):470-8 [PMID: 12644540]
  24. Eur J Radiol. 2020 Feb;123:108774 [PMID: 31841881]
  25. J Thorac Oncol. 2015 Apr;10(4):629-37 [PMID: 25590604]
  26. Science. 2018 Feb 23;359(6378):926-930 [PMID: 29348365]
  27. J Med Screen. 2018 Jun;25(2):110-112 [PMID: 28929865]
  28. Biomed Res Clin Pract. 2018 Dec;3(4): [PMID: 32913898]
  29. PLoS Med. 2017 Apr 4;14(4):e1002277 [PMID: 28376113]
  30. Nat Biomed Eng. 2018 Oct;2(10):719-731 [PMID: 31015651]
  31. JAMA. 2016 Jun 7;315(21):2300-11 [PMID: 27179989]
  32. Eur Respir Rev. 2022 Jan 12;31(163): [PMID: 35022255]
  33. Health Policy. 2022 Sep;126(9):879-888 [PMID: 35750552]
  34. J Natl Cancer Inst. 2007 May 2;99(9):715-26 [PMID: 17470739]
  35. Eur J Cardiothorac Surg. 2023 Oct 4;64(4): [PMID: 37804174]
  36. N Engl J Med. 2013 Feb 21;368(8):728-36 [PMID: 23425165]
  37. Thorax. 2017 Sep;72(9):819-824 [PMID: 28360223]
  38. Nicotine Tob Res. 2020 Aug 24;22(9):1484-1491 [PMID: 31504798]
  39. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  40. JAMA Netw Open. 2023 Sep 5;6(9):e2331155 [PMID: 37721755]
  41. Nat Med. 2019 Jun;25(6):954-961 [PMID: 31110349]
  42. Chest. 2021 Jul;160(1):341-350 [PMID: 33545164]
  43. JTO Clin Res Rep. 2020 Dec 29;2(3):100137 [PMID: 34590000]
  44. J Thorac Oncol. 2016 May;11(5):693-699 [PMID: 26921675]
  45. Ann Intern Med. 2012 Aug 21;157(4):242-50 [PMID: 22910935]
  46. Ann Oncol. 2011 Feb;22(2):383-9 [PMID: 20675559]
  47. Lancet Respir Med. 2023 Aug;11(8):685-697 [PMID: 37030308]
  48. Am J Respir Crit Care Med. 2016 Feb 15;193(4):427-37 [PMID: 26465739]
  49. Eur Radiol. 2021 Jan;31(1):458-467 [PMID: 32728771]
  50. J Transl Med. 2015 Feb 12;13:55 [PMID: 25880432]
  51. Eur Respir J. 2023 May 18;: [PMID: 37202154]
  52. Health Technol Assess. 2016 May;20(40):1-146 [PMID: 27224642]
  53. Radiology. 2020 May;295(2):328-338 [PMID: 32154773]
  54. JAMA. 2021 Mar 09;325(10):962-970 [PMID: 33687470]
  55. JAMA Netw Open. 2019 Mar 1;2(3):e190204 [PMID: 30821827]
  56. Front Pharmacol. 2023 Nov 01;14:1295511 [PMID: 38027000]
  57. Clin Cancer Res. 2017 Nov 15;23(22):7141-7152 [PMID: 28855354]
  58. Invest Radiol. 2018 Aug;53(8):441-449 [PMID: 29543693]
  59. Front Oncol. 2021 May 05;11:603595 [PMID: 34026602]
  60. Ann Am Thorac Soc. 2020 Apr;17(4):503-512 [PMID: 32011914]
  61. Clin Cancer Res. 2017 Apr 15;23(8):1998-2005 [PMID: 27729459]
  62. N Engl J Med. 2020 Feb 6;382(6):503-513 [PMID: 31995683]
  63. J Thorac Oncol. 2019 Oct;14(10):1732-1742 [PMID: 31260833]
  64. Transl Lung Cancer Res. 2021 Feb;10(2):1050-1063 [PMID: 33718044]
  65. Eur Respir J. 2021 Jan 14;57(1): [PMID: 32732334]
  66. Ann Oncol. 2022 Apr;33(4):395-405 [PMID: 35091076]
  67. Lung Cancer. 2020 Sep;147:154-186 [PMID: 32721652]
  68. PLoS Med. 2023 Oct 3;20(10):e1004287 [PMID: 37788223]
  69. Clin Radiol. 2017 May;72(5):401-406 [PMID: 28069160]
  70. Curr Chall Thorac Surg. 2023 Feb 25;5: [PMID: 37016707]
  71. Thorax. 2017 Oct;72(10):912-918 [PMID: 28710339]
  72. Lancet Oncol. 2023 May;24(5):e207-e218 [PMID: 37142382]
  73. J Clin Oncol. 2023 Sep 20;41(27):4341-4347 [PMID: 37540816]
  74. Lung Cancer. 2014 Jan;83(1):51-5 [PMID: 24268382]
  75. Thorax. 2020 Apr;75(4):306-312 [PMID: 32139611]
  76. J Thorac Oncol. 2017 Jan;12(1):77-84 [PMID: 27544059]
  77. Transl Lung Cancer Res. 2021 May;10(5):2347-2355 [PMID: 34164282]
  78. J Clin Oncol. 2014 Mar 10;32(8):768-73 [PMID: 24419137]
  79. Chest. 2018 Sep;154(3):491-500 [PMID: 29496499]
  80. Diagnostics (Basel). 2021 Sep 03;11(9): [PMID: 34573951]
  81. Lancet Public Health. 2023 Feb;8(2):e130-e140 [PMID: 36709053]
  82. CA Cancer J Clin. 2023 Jan;73(1):17-48 [PMID: 36633525]
  83. Ann Am Thorac Soc. 2020 Apr;17(4):399-405 [PMID: 32017612]
  84. Zhongguo Fei Ai Za Zhi. 2018 Feb 20;21(2):67-75 [PMID: 29526173]
  85. Cancer. 2014 Jun 1;120(11):1713-24 [PMID: 24577803]
  86. Chin Med J (Engl). 2023 Jul 20;136(14):1639-1641 [PMID: 37265386]
  87. Oncotarget. 2017 Dec 26;9(5):6346-6355 [PMID: 29464077]
  88. Transl Lung Cancer Res. 2020 Feb;9(1):10-22 [PMID: 32206549]
  89. Eur Respir J. 2011 Jun;37(6):1466-73 [PMID: 21148233]
  90. Front Public Health. 2023 Nov 09;11:1264342 [PMID: 38026274]
  91. Cancers (Basel). 2023 Sep 28;15(19): [PMID: 37835468]
  92. J Thorac Oncol. 2023 Jan;18(1):47-56 [PMID: 37650698]
  93. J Natl Cancer Inst. 2015 Mar 19;107(6):djv063 [PMID: 25794889]
  94. N Engl J Med. 2013 Jul 18;369(3):245-254 [PMID: 23863051]
  95. Lung Cancer. 2021 Nov;161:136-140 [PMID: 34583222]
  96. Thorax. 2024 Mar 15;79(4):307-315 [PMID: 38195644]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0LCSprogrammesLungcancertoolsscreeningemergedrecentyearsaroundworldpresentdifferencesdeliveryinclusioncriteriaresourceallocationnationalscalefullyestablishedanticipatedfollowEvidenceshowncombinationlow-dosechestcomputedtomographyscansmokingcessationofferedpartprogrammeimprovedpatientoutcomesPromisingincluderefinedriskpredictionmodelsusebiomarkersartificialintelligenceradiomicsHoweverrequirestudyclinicalvalidationrequiredpriorroutineimplementationscreening:stand?

Similar Articles

Cited By (2)